Respiratory News and Research RSS Feed - Respiratory News and Research

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

Study: Inactivating polymorphism may influence progression of ovarian and luminal breast cancer

A common polymorphism - a variation in a person's DNA sequence that is found with regularity in the general population - can lead to a chain of events that dictates how a tumor will progress in certain types of cancer, including a form of breast cancer as well as ovarian cancer, according to new research from The Wistar Institute that was published online by the journal Cancer Cell. [More]
Experimental drug warrants clinical study for treatment of Ebola infection

Experimental drug warrants clinical study for treatment of Ebola infection

A case report, published in The Lancet today, describes the successful treatment of Ebola using a new drug under clinical development for vascular leakage (FX06, a fibrin-derived peptide). [More]
Gene variations predispose mestizo Mexican population to develop severe form of COPD

Gene variations predispose mestizo Mexican population to develop severe form of COPD

A study by Ramcés Falfán-Valencia, researcher at the National Institute of Respiratory Diseases, found that the mestizo Mexican population has a number of variations in certain genes that predispose them to develop the most severe form of chronic obstructive pulmonary disease (COPD). [More]
More open discussions needed when referring patients for cancer investigation, study says

More open discussions needed when referring patients for cancer investigation, study says

GPs should consider a more overt discussion with patients when referring them for further investigation of symptoms which may indicate cancer, according to a paper published in the British Journal of General Practice. [More]
Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Pre-clinical studies confirm TRXE-009 as new potential treatment for melanoma

Novogen Limited, Australian/US biotechnology company, today announces that it has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma. [More]
PNNL to share variety of research at 2014 American Geophysical Union Fall Meeting

PNNL to share variety of research at 2014 American Geophysical Union Fall Meeting

Scientists from the Department of Energy's Pacific Northwest National Laboratory will present a variety of research at the 2014 American Geophysical Union Fall Meeting, which runs Monday, Dec. 15 through Friday, Dec. 19 at the Moscone Convention Center in San Francisco. [More]
Scientists validate oral vaccine delivery system to combat global health threats

Scientists validate oral vaccine delivery system to combat global health threats

Scientists at The Forsyth Institute and Tufts University have succeeded in describing and validating a unique system of oral vaccine delivery using a common bacteria found in the mouth. [More]
Study: New flooring can increase risk of respiratory diseases in infants

Study: New flooring can increase risk of respiratory diseases in infants

New flooring in the living environment of pregnant women significantly increases the risk of infants to suffer from respiratory diseases in their first year of life. This is the result of a study carried out by the Helmholtz Centre for Environmental Research and the "St Georg" Municipal Hospital, which demonstrates that exposure to volatile organic compounds in the months before and after birth induces breathing problems in early childhood . [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche announces launch of cobas Liat System for on-demand testing in different settings

Roche today announced the launch of the cobas Liat System—a fast, compact , easy to use, molecular diagnostic platform, designed for on-demand testing in physician clinics, pharmacies and hospital lab settings. [More]
Tips to allergy sufferers for easy breathing this holiday season

Tips to allergy sufferers for easy breathing this holiday season

The many smells and tastes of the holidays that get so many in a festive mood can sicken others, thanks to allergic reactions. But with some seasonal savvy, allergy sufferers can breathe easy this festive time of year. [More]
Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco. [More]
Scientists to explore biology of human asthma by using slime mould

Scientists to explore biology of human asthma by using slime mould

Scientists from Royal Holloway, University of London, will research the biology of human asthma by using a slime mould, an organism which has no lungs but could hold the key to new treatments. [More]

Study: Drive for energy efficient homes could raise asthma risks

The drive for energy efficient homes could increase asthma risks, according to new research. [More]
FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

FDA clears ArmaGen's AGT-182 IND application for treatment of Hunter syndrome

ArmaGen, Inc., a privately held biotechnology company focused on developing novel therapies to treat severe neurological disorders, announced today that the Investigational New Drug (IND) application for the company's lead product candidate, AGT-182 for the treatment of Hunter syndrome, has been accepted by the U.S. Food and Drug Administration and is now active. [More]
Study examines benefits of IS technique in assessing effect of pollution on urban asthmatic children

Study examines benefits of IS technique in assessing effect of pollution on urban asthmatic children

For the firefighters and rescue workers conducting the rescue and cleanup operations at Ground Zero from September 2001 to May 2002, exposure to hazardous airborne particles led to a disturbing "WTC cough" -- obstructed airways and inflammatory bronchial hyperactivity -- and acute inflammation of the lungs. At the time, bronchoscopy, the insertion of a fiber optic bronchoscope into the lung, was the only way to obtain lung samples. But this method is highly invasive and impractical for screening large populations. [More]
Higher human exposure to metal cadmium can lead to shorter telomeres

Higher human exposure to metal cadmium can lead to shorter telomeres

A new study led by a researcher at Milken Institute School of Public Health at the George Washington University looks at the metal cadmium and finds that higher human exposure can lead to significantly shorter telomeres, bits of DNA at the ends of chromosomes that are associated with cardiovascular disease, diabetes and other diseases of old age. [More]
Golden Jubilee National Hospital first to use revolutionary technology in rib fracture surgery

Golden Jubilee National Hospital first to use revolutionary technology in rib fracture surgery

The Golden Jubilee National Hospital recently became the first hospital in Scotland to use a revolutionary new technology on a patient suffering from a severe rib fracture. [More]
Excess mortality in schizophrenia ‘not attributable to antipsychotics’

Excess mortality in schizophrenia ‘not attributable to antipsychotics’

The relationship between antipsychotic use and mortality in people with schizophrenia shows a clear U-shape curve, with the highest risk of death seen in those with no antipsychotic exposure, a Swedish cohort study has found. [More]
MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

MOVENTIG (naloxegol) receives EC approval for treatment of opioid-induced constipation

Nektar Therapeutics reported partner AstraZeneca today announced that MOVENTIG (naloxegol) has been granted Marketing Authorisation by the European Commission for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). [More]